ArticleJournal of nanobiotechnology2025
Atosiban-conjugated 3WJ-pRNA nanoparticles delivering GAS1-enhanced extracellular vesicles: targeting the decidua to combat recurrent miscarriage.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundRecurrent miscarriage (RM) remains a significant clinical challenge due to insufficient understanding of decidual microenvironment dysfunction and limited effective therapeutic options. Current treatments primarily focus on immunomodulation and hormonal therapy, which often fail to address the underlying decidual communication defects. This study investigates growth arrest-specific gene 1 (GAS1) as a potential therapeutic target for RM by elucidating its role in extracellular vesicle (EV)-mediated decidual communication and developing a novel RNA nanotechnology-based delivery system for targeted uterine treatment.
resultsGAS1 is identified as a critical regulator of the biogenesis of EVs in decidual stromal cells (DSCs), and its deficiency is strongly associated with pregnancy-related pathologies. Mechanistic investigations suggest that GAS1 modulates RAB39B, a key regulator involved in EV biogenesis and transport, potentially contributing to decidual homeostasis. EVs derived from GAS1-overexpressing DSCs (GAS1-EVs) are enriched in GAS1 protein, forming a self-reinforcing loop for decidual support, while their reprogrammed cargo facilitates embryonic adhesion, trophoblast migration, and angiogenesis. The use of Atosiban-conjugated three-way junction-pRNA (3WJ-pRNA) for the targeted delivery of GAS1-enhanced EVs (Atosiban-GAS1-EVs) to the uterus in early pregnancy is explored, offering a promising non-invasive targeted treatment for women with RM. This targeted approach restores decidual microenvironment organization and reduces fetal resorption rates in murine RM models.
conclusionsThis study unveils that the GAS1-RAB39B axis may play a significant role in EV-mediated decidual communication and provide a potential non-invasive, RNA nanotechnology-driven strategy for RM treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.